|

Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study

RECRUITINGSponsored by Mayo Clinic
Actively Recruiting
SponsorMayo Clinic
Started2025-07-31
Est. completion2026-12-31
Eligibility
Age2 Years – 22 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07071051

Summary

This study evaluates the impact of calaspargase pegol (Cal-PEG) on the coagulation system in pediatric patients with acute lymphoblastic leukemia/lymphoma (ALL).

Eligibility

Age: 2 Years – 22 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age 2-21.5 years
* Confirmed diagnosis of acute lymphoblastic leukemia/lymphoma
* Planned treatment with Cal-PEG
* Informed consent obtained from parents or guardians

Exclusion Criteria:

* Pre-existing coagulation disorders
* Known hypersensitivity to asparaginase products
* Liver failure
* Any acute or chronic disease that is known to affect coagulation testing (e.g. nephrotic syndrome)
* Currently pregnant
* Use of systemic blood thinner within 48 hours prior to study blood draw

Conditions3

CancerChildhood Acute Lymphoblastic LeukemiaChildhood Lymphoblastic Lymphoma

Locations1 site

Mayo Clinic in Rochester
Rochester, Minnesota, 55905
Clinical Trialsmayocliniccancerstudies@mayo.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.